Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Generic Daklinza Deal Sets Precedent In HCV Drug Licensing

This article was originally published in Scrip

Executive Summary

The licensing agreement announced on Nov. 23 by the Medicines Patent Pool and Bristol-Myers Squibb, under which generics firms will be able to manufacture their own versions of the firm's hepatitis C drug daclatasvir for sale in more than a hundred lower-income countries, breaks new ground in several different ways.


Related Content

Cadila-Hetero Slugfest Over The 'Hep' Tag